Complement Therapeutics
Research - London, England, United Kingdom
Complement Therapeutics Employees
Complement Therapeutics Senior Management
Complement Therapeutics Details
Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
Complement Therapeutics Technologies
Email Providers
Outlook
Load Balancers
Nginx
CMS
WordPress.org
Other
Mobile Friendly